Boston 'still committed' to renal denervation
This article was originally published in Clinica
Executive Summary
Boston Scientific “still believes” in its Vessix renal denervation technology, a spokesperson has told Clinica. He acknowledged that the failure of Medtronic’s Symplicity device in the HTN-3 study in January had cast doubts on the technique, which is used in drug-resistant hypertension.